How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

549 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis - Full Text View - Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. Identifier: NCT00878072 Recruitment Status : Completed First Posted : April 8, 2009 Last Update

2009 Clinical Trials

42. Safety and effectiveness of the herpes zoster vaccine to prevent postherpetic neuralgia: 2014 update and consensus statement from the Canadian Pain Society

it be given to individuals who are taking high doses of corticosteroids (>20 mg/day of prednisone) or other immunosuppressive drugs. POSITION 3 Drug treatment (eg, antivirals, corticosteroids) of active shingles has not been shown to decrease the risk of PHN Rationale: Shingles can be treated with antiviral drugs such as acyclovir, famciclovir and valacyclovir. However, these drugs are effective only if given within 72 h of the first signs of the initial pain or rash. Antivirals have been shown

2015 CPG Infobase

43. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. (PubMed)

Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Genital herpes is caused by herpes simplex virus 1 (HSV-1) or 2 (HSV-2). Some infected people experience outbreaks of genital herpes, typically, characterized by vesicular and erosive localized painful genital lesions.To compare the effectiveness and safety of three oral antiviral drugs (acyclovir, famciclovir and valacyclovir) prescribed to suppress genital herpes outbreaks in non (...) trials including patients with recurrent genital herpes caused by HSV, whatever the type (HSV-1, HSV-2, or undetermined), with at least four recurrences per year (trials concerning human immunodeficiency virus (HIV)-positive patients or pregnant women were not eligible) and comparing suppressive oral antiviral treatment with oral acyclovir, famciclovir, and valacyclovir versus placebo or another suppressive oral antiviral treatment.Two review authors independently selected eligible trials

Full Text available with Trip Pro

2014 Cochrane

44. Antiviral treatment for preventing postherpetic neuralgia. (PubMed)

) of antiviral treatment given within 72 hours after the onset of herpes zoster for preventing PHN. There were no language restrictions.Two authors independently selected trials, evaluated the risk of bias in included trials, and extracted and analysed data.Six RCTs with a total of 1211 participants were eligible; five trials evaluated oral aciclovir, and one, with 419 participants, evaluated oral famciclovir. We were able to conduct meta-analyses as there were sufficient similarities in the included studies (...) ). In four of the trials (692 participants), there was some evidence for a reduction in the incidence of pain four weeks after the onset of rash. In the trial of famciclovir versus placebo, neither 500 mg nor 750 mg doses of famciclovir reduced the incidence of herpetic neuralgia significantly. The most commonly reported adverse events were nausea, vomiting, diarrhoea and headache for aciclovir, and headache and nausea for famciclovir. For neither treatment was the incidence of adverse events

2014 Cochrane

45. Chickenpox in Pregnancy

that there is no increase in the risk of major fetal malformation with aciclovir exposure in pregnancy. 42–44 A Danish registry-based cohort study of 837 795 live births between 1996 and 2008 43 reported the pregnancy outcome in 1804 pregnancies exposed to aciclovir, valciclovir or famciclovir in the first trimester. The rate of major birth defects in the exposed group was 2.2% compared to 2.4% in the unexposed (adjusted prevalence odds ratio 0.89, 95% CI 0.65–1.22). The most common antiviral drug used was aciclovir (...) systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984–99. Birth Defects Res A Clin Mol Teratol 2004;70:201–7. 43. Pasternak B, Hviid A. Use of acyclovir, valacyclovir and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010;304:859–66. 44. Mills JL, Carter TC. Acyclovir exposure and birth defects: an important advance, but more are needed. JAMA 2010;304:905–6. 45. Daley AJ, Thorpe S, Garland SM. Varicella

2015 Royal College of Obstetricians and Gynaecologists

46. Management of Genital Herpes in Pregnancy

effects have been reported. Aciclovir is well tolerated in pregnancy. For treatment courses no dose adjustment is necessary. 23,24 There is no evidence of an increased risk of birth defects with aciclovir, famciclovir or valaciclovir if used in the first trimester. 22 Safety data for aciclovir may be extrapolated to valaciclovir in late pregnancy, as it is the valine ester, but as there is less experience with the use of valaciclovir or famciclovir, they are not recommended as a first- line treatment (...) , Sørensen HT. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis 2003;35:255–9. 22. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010;304:859–66. 23. Frenkel LM, Brown ZA, Bryson YJ, Corey L, Unadkat JD, Hensleigh PA, et al. Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol 1991;164:569

2014 Royal College of Obstetricians and Gynaecologists

47. Herpes zoster involving the abducens and vagus nerves without typical skin rash: A case report and literature review. (PubMed)

for VZV DNA was positive at the skin lesion. The patient was diagnosed as having herpes zoster associated with vagus and sixth nerve palsy.She received famciclovir at a dose of 500 mg 3 times daily for 7 days and coadministered methylprednisolone. At the 4-month follow-up, her diplopia and eye movement had resolved completely.In patients with abducens nerve palsy without typical vesicular lesion, herpes zoster may not be detected early. In that case, systemic examination is very important

2019 Medicine

49. Shingles

is healthcare professionals working within the NHS in the UK, and providing first contact or primary health care. How up-to-date is this topic? How up-to-date is this topic? Changes Changes May 2018 — minor update. Eligible ages for shingles vaccination updated in line with PHE guidance. See . October 2017 — minor update. Addition to adverse effects of seizure for famciclovir. January 2017 — minor update. Correction made to advice on NSAIDs for children with shingles. November to December 2016 — reviewed (...) or widespread rash or multiple dermatomal involvement; immunocompromised children; or pregnant or breastfeeding women. For more information on these groups (and other people who may need admission to hospital, referral, or management guided by a specialist) see the section on . If specialist advice or referral is not required, start oral aciclovir, valaciclovir, or famciclovir (use clinical judgement, taking into account cost and compliance issues for each individual) within 72 hours of rash onset

2017 NICE Clinical Knowledge Summaries

52. UK National Guideline for the Management of Anogenital Herpes

with the probability of this over HSV-2 being greater at younger age, (females 500) although there is very limited trial evidence to support this approach. One trial with famciclovir has reported this effect. 85 Dosage of antivirals • Providing there is no evidence of immune failure standard doses of antivirals should suffice (Ib,A). In those with advanced disease it may be necessary to double the standard dose and to continue therapy beyond 5 days (Ib,B). Currently there is no evidence to support the use (...) be substituted. In others, where the pre-treatment pattern of recurrences resumes, suppressive treatment may need to restart (Evidence level IV, C) • Recommended drug regimens for daily suppressive treatment 23,86,87 o Aciclovir 400 mg orally twice to three times a day o Valaciclovir 500 mg orally twice a day • If these options do not adequately control disease then the first option should be to double the dose. If control is still not achieved then famciclovir 500 mg orally twice a day can be tried. (IIa,B

2015 British Association for Sexual Health and HIV

53. Pharmacologic Interventions for Bell's Palsy

% confidence intervals [CI], -18% to 17.6%). However, the analysis lacked the statistical precision to exclude an important beneficial effect (or harm) from the addition of valacyclovir. A Class IV study observed a significant improvement in recovery (RD 26.6%) between patients with severe Bell palsy treated with prednisone alone and patients with severe Bell palsy treated with prednisone plus famciclovir (House-Brackmann Scale score of 5 or 6). This study had a high risk of bias because

2014 National Guideline Clearinghouse (partial archive)

56. Variation in the Reported Management of Canine Prolapsed Nictitans Gland and Feline Herpetic Keratitis (PubMed)

FHV-1 keratitis with topical antibiotics (76.4%), with a minority suggesting topical antivirals (32.2%). GPs favoured topical acyclovir whilst PGs more frequently recommended topical trifluorothymidine. A significantly larger proportion of PGs nominated systemic famciclovir and lysine supplement for FHV-1 keratitis. This survey revealed moderate treatment variation for these conditions, both between and within practitioner groups. Additional research is needed to assess the reasons

Full Text available with Trip Pro

2018 Veterinary Sciences

57. A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 in Adults With Recurrent Genital HSV-2 Infection.

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subject must be HSV-2 seropositive Subjects have a history of recurrent genital herpes in the past year Subjects have a negative result on the HIV Ab/Ag assay Subjects must agree to use contraception during study participation Exclusion Criteria: Documented HSV resistance to acyclovir, valacyclovir, famciclovir, or penciclovir History or current evidence of malignancy except for a localized non

2018 Clinical Trials

58. Trial of C134 in Patients With Recurrent GBM

within 2 weeks of scheduled IRS1-chimeric HSV1 administration. Active oral herpes lesion. Concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, cidofovir). Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any other medical condition that precludes surgery . Also, psychiatric illness/social

2018 Clinical Trials

59. Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

to receive during the study any of the following anti-CMV IgG antibody treatment or anti-CMV drug therapy including the following: Cidofovir, CMV hyper-immune globulin, Any investigational CMV antiviral agent/biologic therapy. Has received within 7 days prior to randomization or plans to receive during the study any of the following anti-CMV drug therapy: LET, GCV, VGCV, Foscarnet, ACV, Valacyclovir, Famciclovir. Is a user of recreational or illicit drugs or has had a recent history (within the last year

2018 Clinical Trials

60. Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes (PubMed)

Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes Our previous articles showed that suppressive or preventive treatment with the herbal Gene-Eden-VIR/Novirin reduced the number and duration of genital herpes outbreaks with no adverse effects. These studies also revealed that the herbal Gene-Eden-VIR/Novirin is mostly superior to acyclovir, valacyclovir, and famciclovir drugs in genital herpes. This study tested the effect of Gene-Eden-VIR/Novirin in oral herpes (also

Full Text available with Trip Pro

2018 Journal of Evidence-based Integrative Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>